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Abstract  
Neuronal autophagy has been shown to be increased in numerous excitotoxic conditions 
including neonatal cerebral hypoxia-ischemia (HI). However the role of this HI-induced 
autophagy remains unclear. To clarify this role we established an in vitro model of excitotoxicity 
combining kainate treatment (Ka, 30µM) with hypoxia (Hx, 6% oxygen) in primary neuron 
cultures. KaHx rapidly induced excitotoxic death that was completely prevented by MK801 or 
EGTA. KaHx also stimulated neuronal autophagic flux as shown by a rise in autophagosome 
number (increased levels of LC3-II and punctate LC3 labeling) accompanied by increases in 
lysosomal abundance and activity (SQSTM1/P62 degradation and LC3-II levels in the presence 
of lysosomal inhibitors) and fusion (shown using an RFP-GFP-LC3 reporter). To determine the 
role of the enhanced autophagy we applied either pharmacological autophagy inhibitors (3-
methyladenine or pepstatinA/E64) or lentiviral vectors delivering shRNAs targeting Beclin1 or 
Atg7. Both strategies reduced KaHx-induced neuronal death. A pro-death role of autophagy was 
also confirmed by the enhanced toxicity of KaHx in cultures overexpressing BECLIN1 or ATG7. 
Finally, in vivo inhibition of autophagy by intrastriatal injection of a lentiviral vector expressing a 
Beclin1-targeting shRNA increased the volume of intact striatum in a rat model of severe 
neonatal cerebral HI. These results clearly show a death-mediating role of autophagy in hypoxic-
excitotoxic conditions and suggest that inhibition of autophagy should be considered as a 
neuroprotective strategy in HI brain injuries. 
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Introduction 
Macroautophagy, the main type of autophagy (hereafter called simply autophagy), consists of the 
engulfment of part of the cytoplasm in a multimembrane compartment (autophagosome), which 
then fuses with a lysosome to produce a large secondary lysosome (autolysosome).1 Autophagy is 
essential to the long term health of cells (including neurons) and by preserving cellular 
homeostasis and supplying nutrients, an increase in autophagy can contribute to cell survival in 
some stress conditions such as nutrient and growth factor deprivation or accumulation of toxic 
molecules (pathogens, misfolded proteins, damaged organelles). However, in other situations, 
autophagy can be deleterious and contribute to cell death either by triggering apoptosis or 
necrosis or as an independent cell death mechanism (“autophagic cell death” or type II 
programmed cell death). 2,3 In neurons the question of whether enhanced autophagy promotes cell 
death or cell survival is a subject of considerable debate3-8 especially in excitotoxic conditions 
such as cerebral ischemia. Some studies have suggested a protective role of neuronal autophagy 
in cerebral hypoxia/ischemia (HI)9,10 whereas others have demonstrated a death-mediating role 11-
14. In the standard model of cerebral HI in rodent pups,15 which is widely used for investigating 
the neuropathological processes of perinatal asphyxia, autophagy is greatly increased in dying 
cortical and hippocampal neurons 11,16, but the role of this autophagy in neonatal HI brain injury 
is unclear. Whereas experiments involving pharmacological modulation of autophagy have 
suggested a protective role,9 neuron-specific deletion of the autophagy gene (atg) Atg7 has 
provided evidence for a deleterious effect.11 
The present study aims to clarify the role of enhanced neuronal autophagy in HI-induced 
injury. Excitotoxicity, a pathological process involving the overstimulation of excitatory 
neurotransmitter receptors (mainly to glutamate), and hypoxia/reoxygenation-induced detrimental 
pathways are considered as central players in neuronal death after HI. Our aim was to develop an 
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in vitro model involving doses of an excitotoxin and hypoxia that were toxic in combination but 
not when used separately so as to imitate as closely as possible the situation in hypoxic-ischemic 
brain damage. For the reasons explained above and in Results, we selected as excitotoxin kainate 
(Ka), a potent glutamate receptor agonist that targets non-NMDA glutamate receptors. 
Furthermore, Ka induces both excitotoxicity17,18 and autophagy in vitro19 and in vivo.18,20 Ka 
treatment was applied in a hypoxic environment since hypoxia can exacerbate the mitochondrial 
production of reactive oxygen species (ROS), especially H2O2 and O2-, which can regulate 
autophagy21-25 or inversely autophagy can contribute to oxidative stress by its involvement in 
ROS accumulation.26,27 We here show that the combination of Ka and hypoxia (KaHx) activates 
autophagy and that this mediates neuronal death as demonstrated by the protective effects of 
downregulating two important Atg proteins, BECLIN1 (BECN1) and ATG7, and by the 
sensitization to KaHx when both proteins are upregulated. Importantly, the downregulation of 
BECN1 in a rat model of neonatal HI affords neuroprotection. Taken together these results 
provide strong evidence for a death-mediating role of enhanced autophagy in HI neuronal injury.      
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Results 
Kainate/hypoxia treatment induces excitotoxic neuronal death 
In order to develop an in vitro model of cerebral asphyxia, we subjected cultured neurons to 
hypoxia and excitotoxicity since these are known to be the main mediators of hypoxic-ischemic 
neuronal death. In initial experiments with NMDA as excitotoxin, we failed to find a dose that 
was toxic in combination with hypoxia but not in isolation (see Introduction), but further 
experiments with Ka fulfilled this criterion. Thus, primary cortical neurons were subjected to 
both 30 µM kainate (Ka) and hypoxia (Hx) at 6% of oxygen for 30 min. Whereas the separate 
treatments with Ka or Hx were found not to be neurotoxic, their combination was highly effective 
in promoting neuronal cell death as shown by a strong increase in PI-positive nuclei at 3h and 6h 
after KaHx treatment (Fig. 1).  
To characterize further this KaHx-induced neuronal death, we pre-treated cortical neuronal 
cultures with either EGTA (a chelator of extracellular calcium) (5 mM) or the NMDA receptor 
antagonist MK801 (40 μM). Both pre-treatments were strongly neuroprotective against KaHx 
treatment (Fig. S1A). These results demonstrate that the KaHx-induced neuronal death is 
calcium-dependent and mediated by NMDA receptors, even though Ka does not directly activate 
NMDA receptors.  
 
Inhibition of apoptosis did not prevent kainate/hypoxia-induced neuronal death 
We investigated whether KaHx treatment induced apoptosis, using also the classical apoptotic 
stimulus, staurosporine (STS) (1μM),28 as a positive control. KaHx-induced neuronal death, 
unlike that induced by STS, appeared to be caspase-independent. This was suggested by a very 
weak activation of caspase-3 (Fig. S2A) and was confirmed by the fact that apoptosis inhibition - 
either by overexpression of the anti-apoptotic protein BCL2 or by treatment with the pan-caspase 
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inhibitor Q-VD-OPH- failed to protect neurons against KaHx. Overexpression of BCL2 (Fig. 
S2B), which was very efficient in preventing STS-induced CASPASE-3 (CASP3) activation 
(Fig. S2C), and eliminated the weak KaHx-induced CASP3 activation that was induced by KaHx 
(Fig. S2D), was unable to protect cortical cultured neurons against KaHx-induced cell death (Fig. 
S2E). A similar lack of protection was observed when KaHx-treated neurons were pre-treated 
with the pan-caspase inhibitor Q-VD-OPH (25 µM) (Fig. S2F).  
 
Kainate/hypoxia treatment enhances neuronal autophagy 
To investigate whether autophagy could be involved in KaHx-induced neuronal death, the effect 
of KaHx treatment on autophagosome formation was studied. As shown in Figure 2A, KaHx-
treated neurons showed more autophagosomes compared to control conditions as demonstrated 
by an increase both in LC3-II expression by immunoblot (Fig. 2A) and in the number of LC3-
positive dots per neuron revealed by immunocytochemistry and confocal microscopy (Fig. 2B) at 
3h and 6h following KaHx treatment. Furthermore, we also showed that this KaHx-induced 
autophagosome accumulation is dependent on NMDA receptor stimulation and extracellular Ca2+ 
since pre-treatment with either MK801 or EGTA were able to prevent the LC3-II increase 
induced by KaHx treatment (Suppl. Fig. 1B). Individual treatments with Ka or Hx did not result 
in any significant change in LC3-II expression (Suppl. Fig. S3). 
The effect of KaHx on lysosomes was then evaluated using immunocytochemistry against 
LAMP1 (Lysosomal Associated Membrane Protein 1) (Fig. 2C) and CATHEPSIN B (CTS B) 
(Fig. 2D). KaHx induced not only an increase in the number of both LAMP1- (Fig. 2C, left 
histogram) and CTS B-positive (Fig. 2D, left histogram) dots, but also an increase in the size of 
both LAMP1- (Fig. 2C, right histogram) and CTS B-positive dots (Fig. 2D, right histogram) as 
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shown by a rise in the number and the percentage of the largest dots (>0.5µm2) which are 
presumably autolysosomes produced by fusion between autophagosomes and lysosomes. 
 
Finally, to demonstrate definitively that KaHx induced an increase in the autophagic flux, 
additional experiments were conducted. First, decreased expression of SQSTM1/P62, a long-
lived protein preferentially degraded by autophagy, was shown at 3 h and 6 h after KaHx 
treatment as shown by immunoblot (Fig. 3A). Moreover, treatments with Ka or Hx alone did not 
result in any significant change in SQSTM1/P62 expression (Suppl. Fig. S3A), which is as 
expected since these separate treatments did not enhance autophagy. To check that the decrease 
in SQSTM1/P62 expression after KaHx was not due to an effect on its production, we did 
additional experiments using a dose of 1µg/µl cycloheximide (CHX), which prevents more than 
95% of the protein synthesis. CHX treatment for 6 h significantly decreased SQSTM1 expression 
as expected. But, importantly, in the presence of CHX the stimulus KaHx (6 h) still induced a 
significant decrease in SQSTM1 expression, supporting the KaHx-induced enhancement of 
autophagic flux (Suppl. Fig. S3B). Then, cortical neurons were pre-treated with a combination of 
the lysosomal enzyme inhibitors E64 (10 μg/ml) and pepstatin A1 (PepA) (10 μg/ml). The KaHx-
induced accumulation of LC3-II was greater in E64/PepA-treated cultures than in untreated 
cultures (Fig. 3B), showing that KaHx treatment induced the neoformation of autophagosomes. 
To further confirm an increase in the autophagic flux induced by KaHx and to demonstrate that 
KaHx did not impair the autophagosome/lysosome fusion process, autophagic flux was 
monitored with the tandem mRFP-GFP-LC3–expressing plasmid ptfLC3 (Fig. 3C and D) 29. 
KaHx induced an increase in both the number of early autophagosomes (yellow dots, before 
fusion) and late autophagosomes (red dot, after fusion with the lysosome) per neuron after both 
3h and 6h of KaHx treatment.  
 8 
Taken together, these results clearly demonstrate that KaHx treatment induced an enhancement of 
the autophagic flux.   
 
Autophagy contributes to kainate/hypoxia-induced neuronal death 
Having demonstrated that autophagy is induced by KaHx treatment, the next step was to evaluate 
the functional role of this enhanced autophagy in KaHx-induced cell death. First, the effect of 
pharmacological inhibition of autophagy with 3-methyladenine (3-MA) was tested. As expected, 
pre-treatment with 3-MA (10 mM) prevented the increases in both LC3-II expression and 
SQSTM1/P62 degradation (Fig. 4A). Then 3-MA treatment displayed a significant 
neuroprotective effect as demonstrated by a decrease in PI-positive nuclei 6h after KaHx 
treatment (Fig. 4B). We also evaluated the effect of lysosomal enzyme inhibition on KaHx-
induced neuronal death by using combined treatment with the above-mentioned cocktail of E64 
and PepA. Pre-treatment with E64/PepA, that efficiently blocked autophagic degradation (Fig. 
3B), significantly reduced neuronal death induced by KaHx (Fig. 4C).   
 To confirm this death-promoting role of enhanced autophagy in KaHx-induced neuronal 
death, we performed knock-down of two different autophagy genes (Atg7 and Becn1) using 
lentiviral vectors encoding short hairpin RNAs (shRNAs). Transduction of cultured cortical 
neurons with Atg7- and Becn1-targeting shRNA vectors resulted in large reductions in the levels 
of the corresponding proteins (Fig. 5A and B). As expected, downregulation of both ATG7 and 
BECN1 decreased KaHx-induced autophagy as shown by both a decrease in autophagosome 
formation (47% and 57% reduction in LC3-II for shRNAs targeting Atg7 and Becn1 respectively) 
and the inhibition of SQSTM1/P62 degradation (Fig. 5C and D). Quantification of PI-positive 
nuclei or of lactate dehydrogenase release 6h after KaHx treatment demonstrated a significantly 
reduced toxicity in Atg7 shRNA and Becn1 shRNA transduced neurons, confirming a pro-death 
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role of autophagy following KaHx treatment (Fig. 5E and F, Suppl. Fig. S4A). This 
neuroprotective effect was still observed at 24h after KaHx treatment (Suppl. Fig. S4A and 
S4B).  
To corroborate these results, we overexpressed BECN1 and ATG7 in cortical neuronal cultures 
using lentiviral vectors encoding ATG7-myc and BECN1-myc. Expecting that KaHx-induced 
neuronal death would occur more rapidly when ATG7 and BECN1 were overexpressed, we 
chose an earlier time-point (3h) point for the overexpression experiments. Overexpression of 
either BECN1 or ATG7 (Fig. 6A and B) resulted in an increased autophagic response to KaHx as 
shown by significantly higher expression of LC3-II and reduced expression of SQSTM1/P62 
(Fig. 6C and D). Furthermore, overexpression of ATG7 or BECN1 exacerbated KaHx-induced 
neuronal death, as shown by increased numbers of PI-positive neurons 3h after KaHx treatment 
in both cases (Fig. 6E and F). 
Since apoptosis and autophagy share common regulators we investigated the effect of apoptosis 
inhibition on KaHx-induced autophagy. Neither BCL2 overexpression using lentiviral vectors 
(Fig. S2) nor caspase inhibition using Q-VD-OPH (data not shown) had any effect on KaHx-
induced autophagy. 
 
Autophagy is increased and involved in neonatal cerebral hypoxic-ischemic brain injury 
The functional role of autophagy in in vivo pathological situations involving hypoxic-excitotoxic 
brain injuries was then investigated. We had previously shown that neonatal cerebral hypoxia-
ischemia (HI) enhanced neuronal autophagy in the cortex and the CA3 region of the 
hippocampus 16, and we here show that a similar enhancement of autophagy occurred in the 
striatum in the same HI model. We selected the striatum rather than the cortex for the in vivo 
experiments because the striatum’s spheroidal form and limited extent permitted us to knock 
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down genes throughout the entire structure using lentiviral vectors (Suppl. Fig. S5). Autophagy 
is enhanced at 24h after the insult by an increase in LC3-II level (Fig. 7A), and by an increase in 
the number of autophagosomes in striatal neurons double-immunolabeled with the neuronal 
marker NeuN and LC3 (Fig. 7B). Moreover, immunoblots revealed that neonatal HI decreased 
the striatal levels of SQSTM1/P62 expression, also at 24h after HI (Fig. 7C). Histochemistry for 
β-hexasosaminidase, a lysosomal enzyme, revealed a strong increase of β-hexasosaminidase-
positive dots detected at 24h after HI compared to sham animals (Fig. 7D). Taken together, these 
results showed that autophagy is strongly increased in the striatum after neonatal cerebral HI. 
The role of this enhanced autophagy in striatum after neonatal cerebral HI was investigated by 
downregulation of BECN1 by intra-striatal injection of lentiviral vectors expressing Becn1 
shRNA, which decreased BECN1 expression by 30% (Fig. 8A). At 24h after HI, BECN1 knock-
down reduced the HI-induced LC3-II increase and SQSTM1 degradation (Fig. 8B), and increased 
the percentage of striatal intact tissue (Fig. 8C). Thus, our in vivo results provide evidence for a 
death-mediating role of autophagy in neonatal cerebral HI. 
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Discussion 
It is now generally recognized that autophagic processes are activated in excitotoxic conditions, 
and notably cerebral ischemia. Increased numbers of autophagosomes have been described in 
different in vitro situations of excitotoxicity such as long treatment and/or high doses of 
NMDA30,31 or Ka,19 or exposure to a specific glutamate uptake inhibitor.32 The injection of toxic 
doses of Ka into the adult mice hippocampus20,33 or striatum34,35 also induces autophagy. 
Numerous in vivo studies of cerebral ischemia or HI over the past twenty years have likewise 
shown enhanced neuronal autophagy (autophagosome formation and lysosomal activity).13,14,36-42 
Controversies remain, however, concerning the role of the autophagic activation in excitotoxic 
conditions both in vitro and in vivo. Even though most of the papers demonstrate a pro-death 
function of autophagy,11-14,27,31,33,34,37,43,44 some studies suggest the opposite.9,10,45-49 These 
discrepancies could be due to differences in the excitotoxic conditions, to the use of 
pharmacological inhibitors with limited specificity50,51 or to the lack of complete analysis on 
autophagy flux, i.e. demonstration that autophagosome increase is not due to lysosomal 
dysfunction in excitotoxic situations. We here resolve these problems and provide clear evidence 
that neuronal autophagy in hypoxic-excitotoxic conditions is deleterious. 
 The combination of two stimuli, a low dose of Ka and moderate hypoxia (6% O2), each of 
which are nontoxic when applied for a very short period (30min), produces a powerful and 
synergetic excitotoxic stimulus. By comparison with the in vivo situation, 6% O2 is in fact 
normoxic, not hypoxic, but when neurons cultured in standard conditions (at 21% O2) are 
exposed to 6% O2 this constitutes a hypoxic stress, probably because they have reduced 
mitochondrial function compared with ones cultured at 5% or 2% O2.52 It has been shown that Ka 
is more potent than NMDA in release of endogenous glutamate.53 Moreover different studies 
support the essential role of KA receptors (Gluk2, Gluk4) in excitotoxicity both in vitro and in 
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vivo, partially involving MAPK activation.54,55 Interestingly, in the rat model of neonatal HI used 
in this study, neither the systemic hypoxia nor the common carotid occlusion alone produces 
brain damage, whereas the combination of both causes a very severe lesion.15 Ka and hypoxia can 
mutually exacerbate their negative effects.56,57 A study in a guinea pig model of perinatal hypoxia 
has shown that hypoxia can decrease the affinity and change the kinetic of desensitization of Ka 
receptors suggesting a potential role of Ka receptors in hypoxia-induced excitotoxicity.58 
Interestingly, in humans a transient developmental elevation in KA binding in early life could 
correlate with the period of vulnerability of this cerebral region to hypoxia-ischemia.59 
 We clearly demonstrated in this study that KaHx enhanced autophagic flux. The number 
of autophagosomes (LC3-positive dots, LC3-II expression level) was increased along with an 
activation of lysosomal activity (shown by degradation of SQSTM1/P62, increase in the number 
and size of lysosomes labeled with LAMP1 or CTS B antibodies) and an increase in 
autophagosome-lysosome fusion (shown with an mRFP-GFP-LC3–expressing plasmid). 
Prevention of this KaHx-induced autophagy, not only pharmacologically with 3-MA but also 
more specifically by downregulating ATG7 or BECN1, significantly decreased neuronal death. 
Moreover upregulation of either protein, which activated autophagy, aggravated the neuronal 
death. These results strongly suggest that enhanced autophagy is involved in KaHx-induced cell 
death. 
In vivo experiments have shown that intrastriatal injection of Ka in adult rats induced an 
excitotoxic injury that was decreased by both pre- and post-treatments with 3-MA.34 More 
recently, both 3-MA injection and ATG7 downregulation have been shown to reduce the loss of 
hippocampal neurons provoked by intraperitoneal administration of Ka.33 Both studies imply that 
autophagy can contribute to Ka-induced apoptosis. However in the present in vitro model, KaHx 
triggers a very rapid and strong neuronal death, with no apparent involvement of apoptosis since 
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neither the pan-caspase inhibitor Q-VD-OPH nor BCL2 overexpression have a protective effect. 
The involvement of caspases is known to vary between excitotoxicity models.60, 61 It  has also 
been shown that 3-MA can suppress the mitochondrial ROS production associated with Ka-
induced excitotoxicity in cultured striatal neurons19. Enhanced autophagy may therefore 
contribute to oxidative stress induced by KaHx. We showed also a protective effect of inhibiting 
lysosomal activity with E64/PepA suggesting that autophagic degradation is involved as well in 
neuronal death. Removal of some protective proteins such as antioxidants26 or generation of toxic 
molecules like ferric iron62 may be implicated. Autophagosomes and (auto)lysosomes have also 
been shown to be potential ROS sources.27  
 There is controversy about the role of the autophagy in neonatal HI. Induction of 
autophagy with the pharmacological agent rapamycin provided some protective effects against 
cerebral HI in rat pups when injected before hypoxia.9 On the other hand, the work of Koike et al. 
(2008)11 demonstrated that ATG7 deficiency specifically in neurons affords strong 
neuroprotection against HI-injury in the hippocampus of neonatal mice. Our results support the 
latter study by showing both in vitro, and for the first time in vivo, that autophagy inhibition by 
knockdown of autophagy genes is neuroprotective. This was the first time that downregulation of 
BECN1 was achieved in vivo requiring the use of lentiviral vectors. This downregulation 
decreased the stress-induced autophagy and reduced the striatal damage induced by HI in rat 
pups. We also previously demonstrated that post-treatment with 3-MA during the 4.5 hours 
following the onset of ischemia decreased by half the volume of the cortical lesion in a model of 
middle cerebral artery occlusion in rat pups.12,43 Most – though not all47,48 - studies of adult 
cerebral ischemia likewise suggest a death-mediating role of autophagy when it is inhibited with 
3-MA,13,27,37 with lysosomal inhibitors13,27,63 or with BECN1 knockdown.14 
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 These results help open the way to possible therapy against neonatal HI by inhibition of 
autophagy, but this would need to be by transient inhibition, since constitutive autophagy is 
required for neuronal health and even survival.64, 65  
 In conclusion our study gives a clear demonstration of the pro-death role played by 
induced autophagy in excitotoxic-hypoxic conditions in cultured neurons and neonatal rats, and it 
consolidates the idea that strategies targeting excessively activated autophagy, to inhibit it 
transiently, should be considered in the development of new therapeutic approaches against 
hypoxic-ischemic brain injuries. 
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Materials and Methods 
Primary cortical neuronal culture. Sprague-Dawley rat pups (from Janvier, France) were 
euthanized in accordance with the Swiss Laws for the protection of animals and were approved 
by the Vaud Cantonal Veterinary Office. Primary neuronal cultures from cortices of 2-day-old 
rats were prepared and maintained at 37°C with a 5% CO2-containing atmosphere in neurobasal 
medium (Life Technologies, 21103-049) supplemented with 2% B27 (Invitrogen, 17504044), 0.5 
mM glutamine (Sigma, G7513) and 100 μg/ml penicillin-streptomycin (Invitrogen) as described 
previously.66 Western blot analyses were done on neurons plated at a density of ~7x105 cells/dish 
(35 mm poly-D-lysine precoated dishes, BD Biosciences, 356467) and immunocytochemistry on 
neurons plated at a density of ~3x105 cells on 12 mm glass coverslips coated with 0.01% poly-L-
lysine (Sigma, P4832 ). Experiments were performed at 12-13 days in vitro (DIV). These cultures 
contain around 10-15% of non-neuronal cells (MAP2 or NeuN-negative). The n values in the 
different results refer to the number of independent experiments, each involving 2 or 3 culture 
dishes or coverslips. Thus, the mean value of 2-3 dishes or coverslips was counted as a single 
observation. 
 
Rat model of perinatal asphyxia. All experiments were performed in accordance with the Swiss 
Laws for the protection of animals and were approved by the Vaud Cantonal Veterinary Office. 
Seven-day old male rats (Sprague Dawley, from Janvier, France) underwent hypoxia-ischemia 
(HI) according to the Rice-Vannucci model15 adapted from the Levine procedure67 as described 
previously.68 Briefly, under isoflurane (3%) anaesthesia, the right common carotid artery was 
isolated, double-ligated (Silkam, 5/0, B/BRAUN Aesculap) and cut. After 2h of recovery with 
the dam, the rat pups were exposed to 2h of systemic hypoxia at 8% of oxygen in a humidified 
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chamber maintained at 35.5°C. Sham operated animals (same anesthetic and surgical procedures 
but without section of the common carotid artery) were used as controls.  
 
Kainate-hypoxia (KaHx) stimulation. Hypoxia was performed for 30 min. in a sealed modular 
incubator chamber (Billups-Rothenberg, MIC-101) that had been flushed for 5 min with a gas 
mixture at 6% of oxygen. At the start of the 30 min. of hypoxia, all the (neurobasal) culture 
medium was replaced with bicarbonate-buffered saline (BBS) solution (NaCl 116mM, KCl 
5.4mM, MgSO4 0.8mM, NaH2PO4 1mM, NaHCO3 26.2mM, Glycine 0.01mM, CaCl2 1.8mM, 
4.5 mg/mL glucose (reagents from Sigma-Aldrich)) previously deoxygenated for 1h30 in the 
hypoxic chamber. Kainate (30 µM) was added immediately after the BBS, and the neuronal 
cultures were thus exposed to KaHx stimulation during the 30min of hypoxia. Then, the BBS was 
removed and replaced with the previous neurobasal medium that had been reserved mixed with 
one-third volume of fresh medium. Thirty minutes in normoxic BBS was used as the control 
stimulation (ct).  
 
Pharmacological treatments. Primary cortical neuronal cultures were pre-treated for 1h with 25 
µM Q-VD-OPH (Quinoline-Val-Asp(ome)-Ch2-O-phenoxy; MP Biomedicals, 030PH10903), 10 
mM 3-methyladenine (3-MA) (Sigma-Aldrich, M9281), 5 mM EGTA (Sigma-Aldrich, E0396)  
or 40 μM MK801 (Sigma-Aldrich, M107). For inhibition of lysosomal degradation, a cocktail of 
10 μg/ml Pepstatin A1 (PepA) (Sigma-Aldrich, P5318) and 10 μg/ml E64 (Sigma-Aldrich, 
E3132) was applied for 6h prior to KaHx stimulation. 
 
Immunoblotting. Cortical neurons or striatal brain tissue were collected in lysis buffer 
(20 mmol/L HEPES, pH 7.4, 10 mmol/L NaCl, 3 mmol/L MgCl2, 2.5 mmol/L EGTA, 
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0.1 mmol/L dithiothreitol, 50 mmol/L NaF, 1 mmol/L Na3VO4, 1% Triton X-100 (reagents from 
Sigma-Aldrich), and a protease inhibitor cocktail (Roche)). Proteins were separated by SDS-
PAGE, transferred on nitrocellulose membrane and analyzed by immunoblotting. Antibodies 
were diluted in a blocking solution containing 0.1% casein and 0.1% Tween 20.  The following 
primary antibodies were used for protein immunodetection: anti-α-tubulin (sc-8035) mouse 
monoclonal, anti-ATG7 (sc-33211) rabbit polyclonal and anti-BECN1 (sc-11427) rabbit 
polyclonal from Santa Cruz Biotechnology (Santa Cruz); anti-LC3 (NB100-2220) rabbit 
polyclonal from Novus Biologicals; anti-cleaved caspase-3 (9661) rabbit polyclonal and anti-
BCL2 (2870) rabbit monoclonal from Cell Signalling Technology; anti-SQSTM1 (P0067) rabbit 
polyclonal from Sigma-Aldrich. After washes in PBS-0.1% Tween, polyclonal goat anti-mouse 
or anti-rabbit IgG secondary antibodies were applied (IRDye 680 (LI-COR, B70920-02) or 
IRDye 800 (LI-COR, 926-32210)). The Odyssey Infrared Imaging System (LI-COR) was used to 
analyze protein bands using Odyssey v1.2 software (LI-COR). OD values were normalized 
against tubulin and expressed as a percentage of values obtained with neurons after control 
stimulation (100%). 
 
Lentiviral vectors. Downregulations of Atg were performed with pLKO lentiviral vectors 
(Openbiosystems) expressing rat specific shRNA sequences from TRC (the RNAi consortium) 
library as described previously:28 a combination of TRCN0000092163 and TRCN0000092166 
for ATG7 (GenBankTM NM_001012097) and TRCN0000033552 for BECN1 (GenBankTM 
NM_053739.2). ATG7 and BECN1 overexpressions were achieved by self-inactivating lentiviral 
transfer vectors under the control of mouse phosphoglycerate kinase 1 (PGK) promoter (SIN-W-
PGK) transducing cDNAs sequences encoding full-length rat Atg7 (GenBankTM 
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NM_001012097) and Becn1 (GenBankTM NM_053739) created using PCR with specific 
primers (Atg7: nucleotides 16-35 (forward), 2092-2112 (reverse); Becn1: nucleotides 225-243 
(forward), 1549-1570 (reverse)) to which the myc-tag encoding sequence was added as explained 
previously.28 Primary cortical neuron cultures were infected at DIV7 with 50ng p24/ml culture 
medium for each vector, and half the medium was replaced on DIV11.  A pLKO vector 
containing scrambled shRNA (Openbiosystems) in Atg knockdown experiments or a SIN-W-
PGK empty vector in ATG upregulation experiments were used as control vectors.  
 
mRFP-GFP-LC3 plasmid transfection and quantification. This plasmid permits the distinction 
between acidic and non-acidic LC3-positive structures, because GFP is acid-sensitive whereas 
RFP is not. Neurons on coverslips were transfected using Lipofectamine 2000 (Invitrogen, 
11668-019) as described previously.69 In brief, two thirds of the medium was removed and 
replaced for 5 h by fresh Neurobasal medium (Life Technologies, 21103-049) plus transfection 
mix with the tandem mRFP-GFP-LC3–expressing plasmid ptfLC3 (Addgene) (1μg of DNA for 
6μl of Lipofectamine). Confocal images were acquired using a Zeiss LSM 710 Meta confocal 
laser scanning microscope. Total LC3-positive dots (GFP+ RFP+ and GFP- RFP+ dots), early 
autophagosomes (GFP+ RFP+ dots) and late autophagosomes (GFP- RFP+ dots) were analyzed 
using ImageJ software and expressed as a number of positive dots per neuron per µm2. 
 
Quantification of cell death with propidium iodide. Cortical neurons on coverslips were washed 
in PBS 1 mM MgCl2 at 4°C and incubated for 10 min in propidium iodide (PI, Sigma-Aldrich, 
P4170) diluted in PBS MgCl2. After PBS washes neurons were fixed in 4% paraformaldehyde in 
0.1M PBS (pH 7.4) for 15 min. A Hoechst staining was performed to visualize the total number 
of nuclei. Coverslips were mounted with FluorSave (Calbiochem, 345-789-20). Cells were 
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examined using a Zeiss Axioplan 2 imaging microscope. Results were expressed as a percentage 
of PI-positive nuclei relative to Hoechst-positive nuclei.  
 
Lactate dehydrogenase release. Cell death was assayed by measurement of lactate 
dehydrogenase released in the medium using the Cytotox 96 non-radioactive cytotoxicity assay 
kit (Promega, G1780) as previously described.66 Lactate dehydrogenase measurements were 
normalized with respect to the values with control vector 6h after KaHx treatment condition. 
 
Intrastriatal injection of lentivirus. Lentiviral vectors were stereotaxically injected in the right 
striatum of 1 or 2-day old rat pups (Suppl. Fig. S5). Rats were anesthetized with isoflurane (3%) 
and positioned in a stereotaxic frame. A midline scalp incision and a small hole were made in the 
skull. A 5.0 µl Hamilton syringe was used for injection at a site specified by the following 
stereotaxic coordinates from Bregma: 0.5 mm anterior, 2.5 mm right and 3 mm depth from the 
skull surface. One µl of lentiviral suspension was infused over 5 min with an automatic injector. 
The needle stayed in place for 2min before a slow removal. Lentiviral suspensions were prepared 
by mixing SIN-W-PGK vector encoding YFP (to visualize the infected area) and pLKO vectors 
encoding control or BECLIN1 shRNA at 1:1 ratio and with a particle content normalized to 
125000 µg p24/ml for each lentivirus. For immunoblotting studies infected striatal tissue was 
dissected under a stereomicroscope with fluorescence (Leica MZ16FA). 
 
Measurement of the surviving striatum after neonatal hypoxia-ischemia. The lesion volumes 
were measured 24h after the insult. Perfused and frozen brains were entirely cut into 50 μm 
coronal sections disposed in series. In a series of cresyl violet stained sections spaced at 500 μm, 
the contralateral striatum and the intact ipsilateral striatum areas were measured using the 
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Neurolucida program (MicroBrightField) and the corresponding volumes were then calculated 
with Neuroexplorer (MicroBrightField). The surviving striatum was then expressed as a 
percentage of contralateral striatum volume.  
 
Immunostaining. Immunostainings were performed on primary cortical neurons that had been 
cultured on coverslips and fixed with 4% paraformaldehyde for 15min, and on 18μm cryostat 
brain sections from rat pups that had been perfused intracardially with the same fixative. 
Blocking and permeabilization were done in PBS with 15% donkey serum and 0.3% Triton X-
100 for 30-45 min. Primary antibodies were diluted in PBS with 1,5% donkey serum and 0.1% 
Triton X-100 overnight at 4°C. Secondary antibodies were diluted in PBS for 2h at room 
temperature. 
The following primary antibodies were used: anti-cathepsin B (06-480) rabbit polyclonal 
antibody from Upstate Biotechnology; anti-NeuN (MAB377) mouse monoclonal antibody and 
anti-MAP2 rabbit (AB5622) from Chemicon; anti-LAMP1 (428017, for rat) from Calbiochem. 
Anti-LC3 was a generous gift from Prof. Yasuo Uchiyama (Tokyo, Japan).  
For immunofluorescence labelling, Alexa Fluor 488 or 594 donkey-anti-rabbit or mouse 
secondary antibodies (Invitrogen) were used and sections or coverslips were mounted with 
FluorSave after a Hoechst staining. A LSM 510 Meta confocal microscope (Carl Zeiss) was used 
for confocal laser microscopy. Images were processed with LSM 510 software and mounted 
using Adobe Photoshop. 
For immunoperoxidase labelling on rat brain sections, endogenous peroxidases were quenched in 
0.3% H2O2 in methanol for 20min before incubation in blocking medium. After the incubation in 
biotinylated secondary antibody (Jackson Immunoresearch), avidin- biotinylated peroxidase 
complex (VECTASTAIN Elite ABC Kit Vector, PK-6200) was added for 2h at room temperature 
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and then developed by incubation with diaminobenzidene (DAB, Roche, 11718096001) substrate 
solution. The sections were dehydrated in graded alcohols and mounted in Eukitt. Sections were 
analyzed using a Zeiss Axioplan 2 imaging microscope. 
 
N-Acetylhexosaminidase histochemistry. Experiments were performed as described previously.12 
Briefly, sections were incubated for 1 hour at 37°C in Fast red violet salt solution (0.63 mol/L 
ethylene glycol monomethyl ether, 1% polyvinyl pyrrolidone, 0.1 mol/L citric acid-citrate buffer 
(pH4.4), 1.6 mol/L sodium chloride, 2.7 mmol/L 5-chloro-4-benzamido-2-methylbenzene-
diazonium chloride (Fast red violet LB salt) (Sigma-Aldrich, F3381) using 0.5 mmol/L naphthol-
AS-BI-N-acetyl-D-glucosaminide (Sigma-Aldrich, N4006) as the substrate. The sections were 
then fixed in 10% formaldehyde, dehydrated in graded alcohols and mounted in Eukitt medium. 
To verify the staining specificity, controls with omission of the substrate or at basic pH (pH 10) 
were done in parallel. Image acquisition was performed with an Axiovision Zeiss microscope. 
 
Statistical analysis. Data are expressed as mean values ± SEM. Data were analyzed statistically 
using JB STAT software. The n values were sufficiently high for the statistical power to be 
greater than 0.8 in all experiments. We first tested each group of data for distribution normality 
using Shapiro-Wilk tests. In case of normal distribution, we used a Welch’s ANOVA test (one-
way ANOVA with unequal variances) followed by a post-hoc Tukey-Kramer test to compare the 
different treatments. When the distribution was not normal, we used a Kruskal-Wallis test (non-
parametric analogue of the one-way ANOVA) followed by a post-hoc Steel-Dwass test to 
compare the different treatments. p < 0.05 was chosen as the threshold for statistical significance. 
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Figure Legends 
Figure 1. Kainate/hypoxia treatment induces neuronal death.  
(A) KaHx induces neuronal death as shown morphologically in brightfield images or by 
combined propidium iodide (PI)-staining (in red, dead cells) and MAP2-immunolabeling (in 
green) 6 h after control and KaHx stimulations. (B) Representative images of PI-stained (in red) 
and Hoechst-stained nuclei (in blue, total cells) of cultured cortical neurons 6 h following 30 min 
of different stimulations: ct: control, KaHx: kainate/hypoxia, Ka: kainate, Hx: hypoxia. (C) 
Quantification of PI-positive nuclei as a percentage of all nuclei showing a rapid and strong cell 
death induced by the combination of kainate and hypoxia whereas the separate treatments were 
not toxic (ct: 5 ± 2%, KaHx 3 h: 44 ± 6%, KaHx 6 h: 59 ± 3%, Ka: 11 ± 2%, Hx 6 ± 2%). Values 
are mean ± SEM, *p < 0.05, ***p< 0.001, Tukey-Kramer test. n = 6 independent experiments. 
Bar = 20 µm.  
 
Figure 2. Kainate/hypoxia increases autophagosome formation and lysosomal markers in 
cultured cortical neurons.  
(A) Representative immunoblot of LC3 (upper part) and the corresponding quantification (lower 
part) showing that LC3-II expression level is upregulated at 3 h and 6 h after kainate/hypoxia 
(KaHx) stimulation. (ct: 100 ± 0%, KaHx 3 h: 160 ± 8%, KaHx 6 h: 185 ± 19%). Values are 
mean ± SEM, ***p< 0.001, Steel-Dwass test. (B) Confocal images of LC3 immunolabeling (in 
red) of representative cultured cortical neurons at 6h after control (ct) or KaHx stimulation (upper 
part), and quantification of LC3-positive dots per neuron per µm2 (lower part) demonstrating a 
strong increase in the number of autophagosomes after KaHx. (ct: 0.028 ± 0.004, KaHx 3 h: 
0.189 ± 0.022, KaHx 6 h: 0.224 ± 0.024). Values are mean ± SEM, Tukey-Kramer test. Bar=20 
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µm. (C) Immunolabeling for the lysosomal marker LAMP1 (in green) shows an increase not only 
in the number of positive dots (upper graph; ct: 0.099 ± 0.006, KaHx 3 h: 0.196 ± 0.009, KaHx 6 
h: 0.210 ± 0.017; Tukey-Kramer test) but also in the percentage of large positive dots (>0.5 μm2) 
(lower graph; ct: 3.3 ± 1.5%, KaHx 3 h: 23.9 ± 3%, KaHx 6 h: 20 ± 4.8%; Steel-Dwass test) after 
KaHx. Values are mean ± SEM. (D) Similar results are obtained with immunolabeling for the 
lysosomal enzyme cathepsin B (CTS B) (in red). This phenomenon occurs in neurons as shown 
by double immunolabeling for CTS B and NeuN (in green). (Upper graph: ct: 0.06 ± 0.01, 3 h 
KaHx: 0.176 ± 0.02, 6 h KaHx: 0.19 ± 0.02) (Lower graph: ct: 3.4 ± 1.2%, 3 h KaHx: 16.1 ± 
1.2%, 6 h KaHx: 16.9 ± 1.7). Values are mean ± SEM, Steel-Dwass test. n≥25. Bar=20µm. *p< 
0.05, **p< 0.01, ***p< 0.001.  n = 4 independent experiments. 
  
Figure 3. Kainate/hypoxia enhances autophagic flux in cultured cortical neurons.  
(A) Representative immunoblots for SQSTM1/P62 (upper part) and the corresponding 
quantification (lower part) indicate that kainate/hypoxia (KaHx) significantly decreases 
SQSTM1/P62 expression. (ct: 100 ± 0%, 3 h KaHx: 76 ± 4%, 6 h KaHx: 73 ± 5%). n = 13 
independent experiments. (B) Representative immunoblots against LC3 and SQSTM1/P62 and 
the corresponding quantifications demonstrate that exposure to pepstatin A (PepA) and E64 in 
cultured neurons increases the level of LC3-II (Pep/E64: 174 ± 13%) and SQSTM1/P62 
(Pep/E64:  144 ± 14 %) relative to control (ct) stimulation, indicating that autophagic degradation 
is prevented. Addition of Pep/E64 6 h before, during or after KaHx treatment (6 h) results in a 
greater increase in LC3-II than treatment with KaHx or E64/PepA alone (Ka+Hx: 169 ± 5%, 
E64/PepA + KaHx: 277 ± 27%) and diminishes the KaHx-induced degradation of SQSTM1/P62 
(Ka+Hx: 78 ± 3%, E64/PepA + KaHx: 118 ± 9%) . Values are mean ± SEM, *p<0.05, **p<0.01, 
***p< 0.001, Tukey-Kramer test. n = 4 independent experiments. (C) Confocal images of 
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representative cultured cortical neurons transfected with the tandem mRFP-GFP-LC3–expressing 
plasmid at 3h and 6h after Ka/Hx. (D) Quantification of the number of LC3-positive dots per 
neuron per µm2 shows an active autophagic flux (TOTAL = GFP+ RFP+ and GFP- RFP+: ct: 
0.03 ± 0%, 3 h: 0.17 ± 0.02%, 6 h: 0.23 ± 0.01%, early autophagosomes = GFP+ RFP+: ct: 0.01 
± 0%, 3 h: 0.10 ± 0.02%, 6 h: 0.13 ± 0.01%,; late autophagosomes = GFP- RFP+: ct: 0.02 ± 0%, 
3 h: 0.07 ± 0.01%, 6 h: 0.10 ± 0.01 %,). Values are mean ± SEM,. **p<0.01, ***p< 0.001. 
Tukey-Kramer test.  n = 4 independent experiments. Bar=20µm. 
 
Figure 4. Pharmacological inhibition of the autophagic process with 3-methyladenine or 
E64/PepstatinA protects cultured cortical neurons against kainate/hypoxia treatment.  
(A) Representative immunoblots against LC3 and SQSTM1/P62 and the corresponding 
quantifications confirm that 3-methyladenine (3-MA) prevents accumulation of LC3-II (KaHx: 
164 ± 14%, 3-MA KaHx: 95 ± 14; Welch ANOVA, n = 5 independent experiments) and 
reduction of SQSTM1/P62 (KaHx: 65 ± 8%, 3-MA KaHx: 110 ± 12%; Welch ANOVA, n = 5 
independent experiments) following exposure to KaHx. (B-C) Quantification of PI-positive 
nuclei as a percentage of all nuclei (Hoechst-stained) demonstrates that inhibition of the 
autophagic process with (B) 3-MA (ct: 6.6 ± 1.4, 3-MA: 8.4 ± 1.9, KaHx: 54.8 ± 2, 3-MA KaHx: 
24.6 ± 4.8, Steel-Dwass test, n = 3 independent experiments) or (C) E64/PepstatinA (PepA) (ct: 
7.9 ± 0.1, E64/PepA: 12.5 ± 1, KaHx: 60 ± 3.8, E64/PepA KaHx: 26.7 ± 7.4, Tukey-Kramer test, 
n = 4 independent experiments) is neuroprotective. Values are mean ±  SEM, *p<0.05, **p<0.01, 
***p< 0.001.  
Figure 5. Inhibition of autophagy by downregulation of ATG7 or BECLIN1 protects 
cultured cortical neurons against kainate/hypoxia treatment.   
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(A-B) Representative immunoblots and corresponding quantifications showing that lentiviral 
transduction of shRNAs against (A) Atg7 or (B) Beclin1 (Becn1) reduces the expression of ATG7 
(53 ± 2%) or BECN1 (43 ± 2%) compared to control vector-transduced neurons. Values are mean 
± SEM, ***p< 0.001, Wilcoxon test. n = 4 independent experiments. (C-D) Downregulation of 
ATG7 or BECN1 inhibits autophagy induced 6h after KaHx. (C) ATG7 downregulation 
significantly reduces LC3-II (control vector KaHx: 163 ± 30%, Atg7 shRNA  KaHx: 68 ± 10%, 
Kruskal-Wallis test, n = 6 independent experiments) as occurs to a lesser extent with (D) BECN1 
downregulation (control vector KaHx: 205 ± 22%, Becn1 shRNA  KaHx: 140 ± 15%, ANOVA, n 
= 5 independent experiments). Knockdown of either protein is however enough to completely 
block SQSTM1/P62 degradation following KaHx (for ATG7: control vector KaHx: 81 ± 2%, 
Atg7 shRNA KaHx: 116 ± 12%, n = 5 independent experiments; for BECN1: control vector 
KaHx: 82 ± 4%, Becn1 shRNA KaHx: 123 ± 7%, Welch ANOVA, n = 7 independent 
experiments). Values are mean ± SEM expressed as a percentage of control (ct) stimulated 
neurons transduced with control vector, **p< 0.01, ***p< 0.001. (E-F) Transduced neurons with 
Atg7 and Becn1 shRNAs are less sensitive to KaHx than control vector transduced neurons as 
demonstrated by a significant decreased number of PI-positive nuclei 6h after the stimulation (for 
ATG7: control vector: 2 ± 0.7%, Atg7 shRNA: 5 ± 2%, control vector KaHx: 62 ± 2%, Atg7 
shRNA KaHx: 46 ± 3%; for BECN1: control vector: 2 ± 0.8%, Becn1 shRNA: 5 ± 1%, control 
vector KaHx: 59 ± 2%, Becn1 shRNA KaHx: 30 ± 4%). Values are mean ± SEM expressed as a 
percentage of all nuclei (Hoechst-stained). **p< 0.01, Steel-Dwass test, n = 8 independent 
experiments. 
 
Figure 6. Upregulation of autophagy by overexpression of ATG7 and BECLIN1 sensitizes 
cultured cortical neurons against kainate/hypoxia treatment.   
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(A-B) Representative immunoblots and corresponding quantifications showing that lentiviral 
transduction of (A) ATG7-myc and (B) BECLIN1 (BECN1)-myc strongly increase expression of 
ATG7 (430 ± 32%) and BECN1 (220 ± 20%) compared with control vector transduced neurons. 
Values are mean ± SEM, Wilcoxon test. n = 4 independent experiments. (C) The very strong 
overexpression of ATG7 enhances the autophagic process induced 3h after KaHx as 
demonstrated by an increase in LC3-II (control vector KaHx: 139 ± 3%, ATG7-myc KaHx: 189 
± 15%, Kruskal-Wallis test, n = 6 independent experiments) and by a reduction of SQSTM1/P62 
(control vector KaHx: 83 ± 1%, ATG7-myc KaHx: 65 ± 5%, Welch ANOVA, n = 5 independent 
experiments). (D) The two-fold increase in BECN1 expression significantly increases the level of 
LC3-II (control vector KaHx: 134 ± 2%, BECN1-myc KaHx: 156 ± 7%, Welch ANOVA, n = 4 
independent experiments) and decreases the level of SQSTM1/P62 (control vector KaHx: 81 ± 
2%, BECN1-myc KaHx: 72 ± 5%, Kruskal-Wallis test, n = 6 independent experiments) 3 h after 
KaHx. Values for (C) and (D) are mean ± SEM expressed as a percentage of control (ct) 
stimulated neurons transduced with control vector. (E-F) Neurons transduced with ATG7-myc 
and BECN1-myc expression vectors are more sensitive to KaHx than control vector-transduced 
neurons as is demonstrated by a significantly increased number of PI-positive nuclei 3h after the 
treatment (for ATG7: control vector: 2.6 ± 0.6%, ATG7-myc: 2.5 ± 1.1%,  control vector KaHx: 
43.3 ± 2.8%, ATG7-myc KaHx: 59.1 ± 3.3%, Steel-Dwass test; for BECN1: control vector: 2.6 ± 
0.6%, BECN1-myc: 3.2 ± 1.2%, control vector KaHx: 43.3 ± 2.8%, BECN1-myc KaHx: 56.8 ± 
5.4%, Tukey-Kramer test). Values are mean ± SEM expressed as a percentage of all nuclei 
(Hoechst-stained). n = 4 independent experiments. *p< 0.05, **p< 0.01, ***p< 0.001.  
 
Figure 7. Neuronal autophagy is enhanced in the striatum after neonatal cerebral hypoxia-
ischemia.  
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Cerebral hypoxia-ischemia (HI) increased the presence of neuronal autophagosomes in the 
striatum of 7-day old rats 24 h after HI as shown by (A) a higher level of LC3-II in immunoblots 
(sh: 100 ± 0%, 6 h: 121 ± 8%, n = 7 rats, 24 h: 166 ± 13%, n = 12 rats, Tukey-Kramer test) and 
(B) by strong punctate LC3-immunolabeling (arrows) in NeuN-positive neurons compared to 
sham-operated animals (sh). Bar = 20 µm. (C) Quantification of SQSTM1/P62 expression level 
by immunoblot shows that neonatal HI induces SQSTM1/P62 degradation (sh: 100 ± 4%, 24 h: 
60 ± 7%, n = 8 rats, Welch ANOVA). Values are expressed as a percentage of sham-operated 
controls. (D) Neonatal cerebral HI increases β-hexosaminidase staining at 24 h compared to sham 
operated animals. Bar = 10 µm. 
 
Figure 8. Inhibition of autophagy by lentiviral vectors expressing shRNA targeting 
BECLIN1 reduces brain damage following neonatal cerebral hypoxia-ischemia.  
(A) Representative immunoblot and corresponding quantification showing that lentiviral 
injections mediating BECLIN1 (BECN1) downregulation decreased BECN1 expression levels by 
30% compared to control lentiviral vector injections (control vector: 100 ± 7%, Becn1 shRNA : 
72 ± 10%), Welch ANOVA, n = 4 rats). When subjected to HI, animals injected with shRNA 
against Becn1 present (B) a reduced induction of LC3-II expression 24 h after the insult (control 
vector: 100 ± 10, Becn1 shRNA : 56 ± 12%, Welch ANOVA, n = 6 rats) and a decreased 
SQSTM1 degradation (control vector: 100 ± 4, Becn1 shRNA : 112 ± 3%, Welch ANOVA, n = 8 
rats). (C) Rat pups with striatal injection of Becn1 shRNA show a higher percentage of “intact 
striatum”, meaning surviving or non infarcted striatum, than do those with control vector-
injection (control vector: 18 ± 2%, n=15; Becn1 shRNA  : 49 ± 7%, n = 12, Welch ANOVA). 
Values are mean ± SEM. *p< 0.05, **p< 0.01. 
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Figure S1. Kainate/hypoxia-induced neuronal death is calcium dependent and 
mediated by NMDA receptors. 
(A) Quantification of PI-positive nuclei as a percentage of all nuclei showing that 
kainate/hypoxia (KaHx)-induced cell death is prevented when neurons are treated with 
either EGTA (chelator of extracellular calcium) or the NMDA receptor antagonist 
MK801. (ct: 9 ± 2%; EGTA: 8 ± 2.%; MK801: 6 ± 2%, KaHx: 58 ± 7%; KaHx+EGTA: 
 1 
18 ± 3%; KaHx+MK801: 6 ± 2%). Steel-Dwass test. n = 6 independent experiments. (B) 
Representative immunoblot of LC3 (upper part) and the corresponding quantification 
(lower part) showing that the increase of LC3-II induced by KaHx does not occur in 
presence of EGTA and MK801. (KaHx: 240 ± 29%, KaHx+MK801: 143 ± 30%, 
KaHx+EGTA: 105 ± 24%). Steel-Dwass test. n = 5 independent experiments. Values are 
mean ± SEM, *p < 0.05, **p< 0.01, ***p< 0.001.  
 
 2 
 Figure S2. Kainate/hypoxia-induced neuronal death is caspase-independent.  
(A) Comparison between the activation of CASPASE (CASP)-3 at 3 h and 6 h after 
kainate/hypoxia (KaHx) stimulation and after staurosporine (STS) exposure (1 μM) 
indicates that the KaHx model involves much less activation of CASP-3 than does the 
 3 
STS model, as shown by representative immunoblots and corresponding quantifications. 
(for KaHx: 3 h: 163 ±  14%, 6 h: 172 ±  14%; for STS: 3 h: 369 ± 19%, 6 h: 703 ± 
100%). Values are mean ± SEM expressed as a percentage of control treatment (30 min 
in BBS medium for KaHx and 0.1% DMSO for STS). *p < 0.05, **p<0.01, ***p< 0.001, 
Steel-Dwaas test. n = 4 independent experiments. (B) Lentiviral transduction of cultured 
cortical neurons with BCL2-myc induces a strong overexpression of BCL2 (BCL2-myc: 
295 ± 43%). Values are mean ± SEM expressed as a percentage of neurons transduced 
with control vector. *p<0.05, Wilcoxon test. n = 4 independent experiments. (C) 
Overexpression of BCL2 completely prevents CASP-3 activation induced by 6 h of STS 
(control vector: 589 ± 58%, BCL2-myc: 111 ± 22%). Values are mean ± SEM expressed 
as a percentage of neurons transduced with control vector and treated with DMSO. 
***p<0.001, Welch ANOVA. n = 4 independent experiments. (D) Overexpression of 
BCL2 blocks KaHx-induced CASP-3 activation (control vector KaHx: 152 ± 10%, 
BCL2-myc KaHx: 93 ± 10%) but does not affect LC3-II (control vector KaHx: 162 ± 
17%, BCL2-myc KaHx: 168 ± 12%) or SQSTM1/P62 (control vector KaHx: 77 ± 3%, 
BCL2-myc KaHx: 76 ± 5%) expression. Values are mean ± SEM expressed as a 
percentage of neurons transduced with control vector after control stimulation. **p<0.01, 
Welch ANOVA. n = 4 independent experiments.  (E-F) Caspase-inhibtion by (E) BCL2-
myc lentiviral transduction (control vector KaHx: 59 ± 5%, BCL2-myc KaHx: 63 ± 8%) 
or (F) by Q-VD-OPH pre-treatment (control KaHx: 59 ± 4%, Q-VD-OPH KaHx: 63 ± 
1%) is not neuroprotective, as is demonstrated by quantification of PI-positive nuclei. 
Values are mean ± SEM expressed as a percentage of all nuclei (Hoechst-stained). n = 4 
independent experiments. 
 4 
 Figure S3. Kainate and hypoxia alone does not enhance autophagy.  
(A) LC3 and SQSTM1 representative immunoblots and the corresponding quantifications 
showing that LC3-II expression level is upregulated (KaHx: 198 ± 32%) and SQSTM1 is 
decreased (KaHx: 74 ± 8%) at 6 h after kainate/hypoxia (KaHx) stimulation whereas both 
treatments have no significant (NS) effect separately (for LC3-II: Ka: 125 ± 12%, Hx: 
116 ± 13%, Steel-Dwaas test; for SQSTM1: Ka: 101 ± 8%, Hx: 109 ± 7%, Tukey-
Kramer test). Values are mean ± SEM. ***p< 0.001. n = 7 independent experiments. (B) 
Representative immunoblots for SQSTM1 and LC3, and the corresponding 
quantifications, demonstrating that kainate/hypoxia (KaHx)-induced SQSTM1 decrease 
persists even in the presence of a protein synthesis inhibitor (1µg/µl cycloheximide, 
CHX, 1h of pre-treatment) (KaHx 6 h: 50 ± 2%, CHX: 65 ± 3%, CHX+KaHx 6 h: 36 ± 
3%). Increase in LC3-II expression is not affected by CHX during the first 6 h (KaHx 6 
 5 
h: 169 ± 8%, CHX: 79 ± 14%, CHX+KaHx 6 h: 162 ± 2%). Values are mean ± SEM.  
***p< 0.001, Tukey-Kramer test. n = 3 independent experiments.  
 6 
  
Figure S4. Inhibition of autophagy by downregulation of ATG7 or BECLIN1 
protects cultured cortical neurons 24 h after kainate/hypoxia treatment.  
(A) Neuroprotective effect of downregulation of ATG7 and BECN1 as shown by the 
quantification of the lactate deshydrogenase (LDH) release in the medium at both 6 h (6 
h: control vector: 12 ± 3%, Becn1 shRNA: 17 ± 6%, Atg7 shRNA: 19 ± 3%, control 
vector KaHx: 100 ± 0%, Becn1 shRNA KaHx: 61 ± 5%, Atg7 shRNA KaHx: 74 ± 8%) 
and 24 h (control vector: 17 ± 8%, Becn1 shRNA: 19 ± 5%, Atg7 shRNA: 21 ± 5%, 
control vector  KaHx: 146 ± 17%, Becn1 shRNA KaHx: 85 ± 8%, Atg7 shRNA KaHx: 93 
± 15%). Values are mean ± SEM expressed as a percentage of the value reached by 
control vector infected neurons 6h after KaHx. *p<0.05, **p<0.01, ***p< 0.001, Steel-
Dwass test, n = 5 independent experiments. (B) Transduced neurons with Atg7 and 
 7 
Beclin) (Becn1) shRNAs are less sensitive to kainate/hypoxia (KaHx) than control vector 
transduced neurons as demonstrated by a significant decreased number of propidium 
iodide (PI)-positive nuclei 24 h after the stimulation (control vector: 5 ± 3%, Becn1 
shRNA: 3 ± 1%, Atg7 shRNA: 2 ± 0.1%, control vector KaHx: 88 ± 2%, Becn1 shRNA 
KaHx: 45 ± 4%, Atg7 shRNA KaHx: 53 ± 4%). Values are mean ± SEM expressed as a 
percentage of all nuclei (Hoechst-stained). ***p< 0.001, Steel-Dwass test, n = 6 
independent experiments.  
 8 
 Figure S5. Intrastriatal lentiviral vector injection. 
Lentiviral vectors stereotaxically injected in the right striatum of 1 or 2-day old rat pups 
infected most of the striatal neurons as demonstrated with a vector transducing a yellow 
fluorescent protein (YFP) (green) 5 days after injection and immunolabelling with the 
neuronal marker NeuN (red). Low magnification of the entire hemisphere was done with 
a stereomicroscope with fluorescence and high magnifications are confocal images. 
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